Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article

Andres Missair, Juan Pablo Cata, Gina Votta-Velis, Mark Johnson, Alain Borgeat, Mohammed Tiouririne, Vijay Gottumukkala, Donal Buggy, Ricardo Vallejo, Esther Benedetti de Marrero, Dan Sessler, Marc A. Huntoon, Jose De Andres, Oscar De Leon Casasola

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cancer causes considerable suffering and 80% of advanced cancer patients experience moderate to severe pain. Surgical tumor excision remains a cornerstone of primary cancer treatment, but is also recognized as one of the greatest risk factors for metastatic spread. The perioperative period, characterized by the surgical stress response, pharmacologic-induced angiogenesis, and immunomodulation results in a physiologic environment that supports tumor spread and distant reimplantation.In the perioperative period, anesthesiologists may have a brief and uniquewindow of opportunity to modulate the unwanted consequences of the stressresponse on the immune system and minimize residual disease. This reviewdiscusses the current research on analgesic therapies and their impact ondisease progression, followed by an evidence-based evaluation of perioperativepain interventions and medications.

Original languageEnglish (US)
Pages (from-to)13-28
Number of pages16
JournalRegional Anesthesia and Pain Medicine
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pain Management
Recurrence
Perioperative Period
Neoplasms
Immunomodulation
Replantation
Psychological Stress
Analgesics
Immune System
Pain
Therapeutics
Research

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Missair, A., Cata, J. P., Votta-Velis, G., Johnson, M., Borgeat, A., Tiouririne, M., ... Casasola, O. D. L. (2019). Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article. Regional Anesthesia and Pain Medicine, 44(1), 13-28. https://doi.org/10.1136/rapm-2018-000001

Impact of perioperative pain management on cancer recurrence : an ASRA/ESRA special article. / Missair, Andres; Cata, Juan Pablo; Votta-Velis, Gina; Johnson, Mark; Borgeat, Alain; Tiouririne, Mohammed; Gottumukkala, Vijay; Buggy, Donal; Vallejo, Ricardo; Marrero, Esther Benedetti de; Sessler, Dan; Huntoon, Marc A.; Andres, Jose De; Casasola, Oscar De Leon.

In: Regional Anesthesia and Pain Medicine, Vol. 44, No. 1, 01.01.2019, p. 13-28.

Research output: Contribution to journalArticle

Missair, A, Cata, JP, Votta-Velis, G, Johnson, M, Borgeat, A, Tiouririne, M, Gottumukkala, V, Buggy, D, Vallejo, R, Marrero, EBD, Sessler, D, Huntoon, MA, Andres, JD & Casasola, ODL 2019, 'Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article', Regional Anesthesia and Pain Medicine, vol. 44, no. 1, pp. 13-28. https://doi.org/10.1136/rapm-2018-000001
Missair, Andres ; Cata, Juan Pablo ; Votta-Velis, Gina ; Johnson, Mark ; Borgeat, Alain ; Tiouririne, Mohammed ; Gottumukkala, Vijay ; Buggy, Donal ; Vallejo, Ricardo ; Marrero, Esther Benedetti de ; Sessler, Dan ; Huntoon, Marc A. ; Andres, Jose De ; Casasola, Oscar De Leon. / Impact of perioperative pain management on cancer recurrence : an ASRA/ESRA special article. In: Regional Anesthesia and Pain Medicine. 2019 ; Vol. 44, No. 1. pp. 13-28.
@article{3049a3fd4d4c43e3a44f5a22af07e8f7,
title = "Impact of perioperative pain management on cancer recurrence: an ASRA/ESRA special article",
abstract = "Cancer causes considerable suffering and 80{\%} of advanced cancer patients experience moderate to severe pain. Surgical tumor excision remains a cornerstone of primary cancer treatment, but is also recognized as one of the greatest risk factors for metastatic spread. The perioperative period, characterized by the surgical stress response, pharmacologic-induced angiogenesis, and immunomodulation results in a physiologic environment that supports tumor spread and distant reimplantation.In the perioperative period, anesthesiologists may have a brief and uniquewindow of opportunity to modulate the unwanted consequences of the stressresponse on the immune system and minimize residual disease. This reviewdiscusses the current research on analgesic therapies and their impact ondisease progression, followed by an evidence-based evaluation of perioperativepain interventions and medications.",
author = "Andres Missair and Cata, {Juan Pablo} and Gina Votta-Velis and Mark Johnson and Alain Borgeat and Mohammed Tiouririne and Vijay Gottumukkala and Donal Buggy and Ricardo Vallejo and Marrero, {Esther Benedetti de} and Dan Sessler and Huntoon, {Marc A.} and Andres, {Jose De} and Casasola, {Oscar De Leon}",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/rapm-2018-000001",
language = "English (US)",
volume = "44",
pages = "13--28",
journal = "Regional Anesthesia and Pain Medicine",
issn = "1098-7339",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Impact of perioperative pain management on cancer recurrence

T2 - an ASRA/ESRA special article

AU - Missair, Andres

AU - Cata, Juan Pablo

AU - Votta-Velis, Gina

AU - Johnson, Mark

AU - Borgeat, Alain

AU - Tiouririne, Mohammed

AU - Gottumukkala, Vijay

AU - Buggy, Donal

AU - Vallejo, Ricardo

AU - Marrero, Esther Benedetti de

AU - Sessler, Dan

AU - Huntoon, Marc A.

AU - Andres, Jose De

AU - Casasola, Oscar De Leon

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cancer causes considerable suffering and 80% of advanced cancer patients experience moderate to severe pain. Surgical tumor excision remains a cornerstone of primary cancer treatment, but is also recognized as one of the greatest risk factors for metastatic spread. The perioperative period, characterized by the surgical stress response, pharmacologic-induced angiogenesis, and immunomodulation results in a physiologic environment that supports tumor spread and distant reimplantation.In the perioperative period, anesthesiologists may have a brief and uniquewindow of opportunity to modulate the unwanted consequences of the stressresponse on the immune system and minimize residual disease. This reviewdiscusses the current research on analgesic therapies and their impact ondisease progression, followed by an evidence-based evaluation of perioperativepain interventions and medications.

AB - Cancer causes considerable suffering and 80% of advanced cancer patients experience moderate to severe pain. Surgical tumor excision remains a cornerstone of primary cancer treatment, but is also recognized as one of the greatest risk factors for metastatic spread. The perioperative period, characterized by the surgical stress response, pharmacologic-induced angiogenesis, and immunomodulation results in a physiologic environment that supports tumor spread and distant reimplantation.In the perioperative period, anesthesiologists may have a brief and uniquewindow of opportunity to modulate the unwanted consequences of the stressresponse on the immune system and minimize residual disease. This reviewdiscusses the current research on analgesic therapies and their impact ondisease progression, followed by an evidence-based evaluation of perioperativepain interventions and medications.

UR - http://www.scopus.com/inward/record.url?scp=85060060845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060060845&partnerID=8YFLogxK

U2 - 10.1136/rapm-2018-000001

DO - 10.1136/rapm-2018-000001

M3 - Article

C2 - 30640648

AN - SCOPUS:85060060845

VL - 44

SP - 13

EP - 28

JO - Regional Anesthesia and Pain Medicine

JF - Regional Anesthesia and Pain Medicine

SN - 1098-7339

IS - 1

ER -